RASolute 302: Evaluating the Side Effect Profile of Daraxonrasib
Key Points
- Daraxonrasib roughly doubled overall survival (OS) compared with chemotherapy for patients with metastatic pancreatic cancer in the RASolute 302 trial.
- The most prominent side effects of daraxonrasib are rash, stomatitis or mucositis, and gastrointestinal (GI) events.
Shiraj Sen, MD, PhD, of NEXT Oncology Dallas, and Raji Shameem, MD, of Orlando Health, discussed data on daraxonrasib from the RASolute 302 trial presented at the 2026 American Society of Clinical Oncology Annual Meeting (ASCO 2026).
Daraxonrasib is a multiselective RAS inhibitor that is effective against a broad range of common mutations in pancreatic cancer, including G12 and Q61 variants. RASolute 302 evaluated daraxonrasib against standard chemotherapy as second-line therapy in patients with metastatic pancreatic adenocarcinoma. After a median follow-up of 8.5 months, the median OSin the overall population was 6.7 months (95% CI, 5.8-8.0) with chemotherapy versus 13.2 months (95% CI, 10.0-not estimable) with daraxonrasib (HR, 0.40; 95% CI, 0.30-0.53; P < .0001), according to the ASCO 2026 plenary session.
The most common treatment-related adverse events with daraxonrasib include rash, mucositis and stomatitis, and GI effects like nausea, vomiting, and diarrhea. Rash typically develops during the first week, and is more manageable if addressed early, said Dr. Sen. Data to guide prophylaxis will emerge as daraxonrasib is implemented in real-world practice.